Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct;116(10):1243-51.
doi: 10.1007/s00702-009-0293-y. Epub 2009 Aug 20.

Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains

Affiliations

Phosphorylation of soluble tau differs in Pick's disease and Alzheimer's disease brains

Janet van Eersel et al. J Neural Transm (Vienna). 2009 Oct.

Abstract

Frontotemporal lobar degeneration (FTLD) is a common cause of presenile dementia characterised by behavioural and language disturbances. Pick's disease (PiD) is a subtype of FTLD, which presents with intraneuronal inclusions consisting of hyperphosphorylated tau protein aggregates. Although Alzheimer's disease (AD) is also characterised by tau lesions, these are both histologically and biochemically distinct from the tau aggregates found in PiD. What determines the distinct characteristics of these tau lesions is unknown. As phosphorylated, soluble tau has been suggested to be the precursor of tau aggregates, we compared both the level and phosphorylation profile of tau in tissue extracts of AD and PiD brains to determine whether the differences in the tau lesions are reflected by differences in soluble tau. Levels of soluble tau were decreased in AD but not PiD. In addition, soluble tau was phosphorylated to a greater extent in AD than in PiD and displayed a different phosphorylation profile in the two disorders. Consistently, tau kinases were activated to different degrees in AD compared with PiD. Such differences in solubility and phosphorylation may contribute, at least in part, to the formation of distinct tau deposits, but may also have implications for the clinical differences between AD and PiD.

PubMed Disclaimer

References

    1. Science. 2005 Jul 15;309(5733):476-81 - PubMed
    1. Proc Natl Acad Sci U S A. 2007 Jun 12;104(24):10252-7 - PubMed
    1. Ann Neurol. 2004 Sep;56(3):399-406 - PubMed
    1. Anal Biochem. 2004 Dec 1;335(1):30-41 - PubMed
    1. Brain Res Brain Res Rev. 2001 Jul;35(3):266-86 - PubMed

Publication types

MeSH terms

Substances